The collection policy to promote three years of multi-differentiation shows what kind of bureau the local leading pharmaceutical companies are in

The third batch of centralized procurement of national drugs just came to an end in August, 194 pharmaceutical companies submitted a total of 354 varieties of quotations, the final 123 enterprises 191 varieties won the bid.
the 191 varieties shortlisted have achieved varying degrees of price reduction.
Through several rounds of national harvesting, we can observe that it is becoming more obvious that, unlike multinational pharmaceutical companies, local pharmaceutical companies participate in the collection of more positive attitude, in line with policies, active price reduction, and strive for the election.
For example, Qilu Pharmaceuticals, which won the crown in the third batch, was selected in 8 varieties, ranking first, with a winning rate of 100%, and 7 of them were selected in first place.
In addition, shi pharmaceutical, Huahai, Colum, China Biopharmaceuticals, Hengrui and other traditional leading enterprises, in the three batches of mining, there are also a large number of products selected, the attitude of local leading enterprises in the collection of more proactive, the number of selected products also contrasted with small and medium-sized enterprises.
, what kind of bottom gas so that these leading enterprises can significantly reduce prices, even won the election? What kind of future do they plan for themselves after the normalization of the collection? 01. The feast of the leader three batches of collection carried out down, which seems to have become the feast of the leading enterprises in China.
alone in the largest number of varieties in the third batch of mining, stone medicine and Qilu 8 varieties of all, for the largest number of enterprises, in addition to Huahai, Xinlitai, Haizheng 100% of the election, and Howson is 6 in 5, Colum 5 in 4, on the drug 8 in 6, the number of local leading enterprises and the selection rate are quite high, and behind these enterprises for the collection policy attention and input.
Pharmaceuticals is undoubtedly one of the most concerned pharmaceutical companies.
first of all, the collection of 8 varieties all selected, 7 products achieved the first place, fully demonstrated Qilu Pharmaceuticals on the reporting market is imperative determination.
From the results of previous batches, Qilu Pharmaceutical has been actively involved in the procurement of volume, and achieved remarkable results: on September 24, 2019, qilu Pharmaceuticals produced five drugs in the expansion of the "4 plus 7" collection;
, Qilu Pharmaceuticals has selected a total of 17 products, the number of TOP3 level.
addition, Huahai, stone medicine and other local leading enterprises have also reaped more than a dozen products selected in the best results.
the future, the advantages of these local leaders may be magnified.
The Standing Committee of the Political Bureau of the Communist Party of China (CPC) Central Committee and Vice Premier Han Zheng chaired a symposium on the centralized belt procurement of pharmaceuticals and high-value medical supplies on the 10th, at which Han Zheng stressed that efforts should be made to consolidate and improve the results of the system, form a more standardized system, promote the normal institutionalization of drug collection and collection by state organizations, and speed up the expansion of the scope of collection.
for drug collection, the central government put forward the words "accelerated", "expanded" and so on, will undoubtedly be good for enterprises with scale and speed.
02. Where's the bottom gas for winning the bid? It is an indisputable fact that generic drugs have entered the era of micro-profits.
the purpose of centralized procurement of drugs organized by the state is to guide the clinical substitution of the original drug and reduce the overall drug price level.
So for the pharmaceutical companies involved in the collection, first of all, we need to have an advantage on the cost side, and not be led upstream by the nose, then, the competition for raw materials will become the focus: the initiative of raw materials in their hands of the enterprise, the situation will inevitably be passive.
of the price of raw materials will directly affect the enterprise's participation in the collection of the quotation "bottom gas", more likely to be directly out of the collection.
control of raw materials and scale has become a strategic focus of the enterprise.
, for example, Qilu Pharmaceuticals, which has selected 17 drugs, has been building the scale and first-in-the-first advantage of generics, expanding its investment in API and preparations, and now has ten production sites.
And at the specific product level, in the first half of this year, the State Drug Administration approved a total of 212 drug batches, involving 146 varieties, Qilu Pharmaceuticals became the biggest winner, a total of 9 generic drug varieties were approved for listing, ranking first, followed by China Biopharmaceuticals, Huahai Pharmaceuticals, Colum Pharmaceuticals and other local giants.
since the 2016 generics conformity evaluation was pushed out, Qilu Pharmaceutical Group has passed the consistent evaluation of 38 drugs, ranking first, of which 22 are more domestic first evaluation, to create a strong product line.
, Qilu, Huahai and other enterprises as the representative of the local leader, in the product is rapidly expanding.
it is worth noting that some companies' products are approved by overseas regulators and sold globally, and that such products often have an advantage in consistent evaluation policies.
such as Huahai, Dongsan, Qilu and so on have laid a world in overseas markets, and products can be recognized by multi-national regulatory agencies, is undoubtedly a recognition of quality.
Qilu's selection of O nitrogen, fumarate novovedimate, giffeitini tablets, etc. have been FDA-certified in the United States, and will be listed in the United Kingdom for sale, Qilu has now achieved 14 preparations exported to the United States.
and Other companies themselves account for an important source of revenue in overseas markets.
is also the advantage and bottom of the local leader.
the above-mentioned meeting, also stressed the need to strengthen the selection of products throughout the life cycle of quality supervision, quality issues to implement "zero tolerance", in accordance with the law.
quality has become a key objective of the collection policy.
03. How to combine internationalization and innovation drive is currently a new strategy for many leading domestic enterprises, but unlike multinational giants, local enterprises in generic drugs, RAW drugs to establish production capacity, market advantages at the same time, accelerate internationalization and innovation capacity-building, that is, often called the combination of imitation, the way out of the country.
" in the world pharmaceutical industry to accelerate the globalization of today, the eyes in the in-house only staring at local competitors, with the international research giant behind, relying on the first imitation, the era of imitation is over.
" Qilu Pharmaceutical Group President Li Yan said, in the global competitive environment, enterprises to stand on the basis of innovation, we must take the road of innovation, to firmly go on.
, Chinese pharmaceutical companies are increasing their investment in research and development, and although there is still a gap with multinational companies, the gap is narrowing.
By the end of 2016, there were 238 listed biopharmaceutical companies in China, with research and development expenditure of 23.151 billion yuan in the current year, and by the first half of 2020, although the number of listed companies had only increased to more than 278, the investment in research and development had far exceeded the figure for the whole of 2016, reaching 35 billion yuan.
Among them, Hengrui, Shipharma and China Biopharmaceuticals invested more than 1.4 billion yuan in research and development in half a year, accounting for more than 10% of revenue, while Qilu Pharmaceuticals, which is not listed, also invested more than 2 billion yuan in research and development in 2019, accounting for about 10% of revenue.
these head companies rely on huge research and development expenditure to form a copy-and-innovation strength pipeline.
, which has developed better, can basically achieve every one to two years an innovative product to market speed.
these innovative products will work with well-patterned generic products to make blood for the enterprise.
since the launch of the national major science and technology special project on the creation of new drugs in 2008, China's biopharmaceutical research and development has made full efforts, and is accelerating the transformation from a large generic drug country to a big country with innovative drugs.
the leading local enterprises selected frequently in the collection, is also one of the leading soldiers in the transformation of China's pharmaceutical industry.